FDA gives emergency approval to Eli Lilly's COVID-19 antibody treatment


The Food and Drug Administration announced on Monday that it has granted emergency authorization of Eli Lilly's COVID-19 treatment for use in certain cases.
The treatment is called bamlanivimab, and it has been approved for use in people who have tested positive for the coronavirus, are 12 and older, and at risk for developing a severe form of COVID-19 or being hospitalized, The New York Times reports. This includes people who are 65 or older and obese, as early studies have shown they can benefit the most from this treatment. It should be administered to a person as soon as possible after they test positive, and within 10 days of developing systems.
In a statement, Eli Lilly CEO David Ricks said bamlanivimab was developed quickly because of "collaboration across the industry and the urgent work being done by the government to ensure appropriate allocation to patients who need it the most." Last month, former New Jersey Gov. Chris Christie (R) received the treatment on an emergency basis after he tested positive for COVID-19.
The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.

Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
The treatment consists of one antibody that is designed to block virus attachment and entry into cells, neutralizing it. Eli Lilly said it expects to have enough treatments to distribute to one million people by the end of the year. On Monday, more than 100,000 new coronavirus cases were reported in the United States, and at least 59,000 people are hospitalized across the country.
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Catherine Garcia has worked as a senior writer at The Week since 2014. Her writing and reporting have appeared in Entertainment Weekly, The New York Times, Wirecutter, NBC News and "The Book of Jezebel," among others. She's a graduate of the University of Redlands and the Columbia University Graduate School of Journalism.
-
Music reviews: Chance the Rapper, Cass McCombs, and Molly Tuttle
Feature "Star Line," "Interior Live Oak," and "So Long Little Miss Sunshine"
-
Film reviews: Eden and Honey Don't!
Feature Seekers of a new utopia spiral into savagery and a queer private eye prowls a high-desert town
-
Critics' choice: Three chefs fulfilling their ambitions
Feature Kwame Onwuachi's grand second act, Travis Lett makes a comeback, and Jeff Watson's new Korean restaurant
-
New York court tosses Trump's $500M fraud fine
Speed Read A divided appeals court threw out a hefty penalty against President Trump for fraudulently inflating his wealth
-
Trump said to seek government stake in Intel
Speed Read The president and Intel CEO Lip-Bu Tan reportedly discussed the proposal at a recent meeting
-
US to take 15% cut of AI chip sales to China
Speed Read Nvidia and AMD will pay the Trump administration 15% of their revenue from selling artificial intelligence chips to China
-
NFL gets ESPN stake in deal with Disney
Speed Read The deal gives the NFL a 10% stake in Disney's ESPN sports empire and gives ESPN ownership of NFL Network
-
Samsung to make Tesla chips in $16.5B deal
Speed Read Tesla has signed a deal to get its next-generation chips from Samsung
-
FCC greenlights $8B Paramount-Skydance merger
Speed Read The Federal Communications Commission will allow Paramount to merge with the Hollywood studio Skydance
-
Tesla reports plummeting profits
Speed Read The company may soon face more problems with the expiration of federal electric vehicle tax credits
-
Dollar faces historic slump as stocks hit new high
Speed Read While stocks have recovered post-Trump tariffs, the dollar has weakened more than 10% this year